Investigating isoquercetin to prevent blood clots in cancer patients
Official title: Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
Funded at Sloan-Kettering Inst Can Research · NIH-11058040 · Data updated 2026-11-12
This study is looking at how isoquercetin, a natural compound found in some foods, can help prevent blood clots in patients with advanced cancer, and it aims to find the best way to use it safely and effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 15, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $631,382 |
| NIH project number | 1R01AT013147-01 |
| Project ID | NIH-11058040 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced cancer who are at high risk for venous thromboembolism.
✕Less likely to help
Patients who do not have cancer or are not at risk for blood clots may not benefit from this research.
What this research studies
This research focuses on isoquercetin, a dietary flavonoid, which has shown promise in inhibiting a protein that contributes to blood clot formation. The study aims to optimize the dosing of isoquercetin for patients with advanced cancer who are at high risk for developing blood clots. Through a combination of laboratory studies and clinical trials, researchers will assess how well isoquercetin works and determine the best way to administer it to maximize its benefits while minimizing risks. Patients may be monitored for changes in specific biomarkers related to blood clotting.
Why it matters
Potential benefit: If successful, this research could provide a new, well-tolerated treatment option for preventing blood clots in cancer patients.
How similar studies have gone: Previous studies have shown promising results with similar flavonoid treatments, indicating potential for success in this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Zwicker, Jeffrey — Sloan-Kettering Inst Can Research
- Study coordinator: Zwicker, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.